CRBU Caribou Biosciences
Caribou Biosciences earnings company data as of 4:47 AM ET 10/22
- 1 of 1 EPS beats
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 11 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 13 Aug | EPS | -0.31 | -0.24 | Beat |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by CRBU's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $12K sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Timothy P Kelly Chief Technology OfficerSale$12K 6,228 shares at $1.93 7.8% of stakeTraded Feb 25 Filed Feb 27
Also filed in the last 12 months, not counted as buying or selling: 6 stock grants and 4 sales to cover taxes.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 2.05,5.02,7.01,8.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.07,9.01 | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| DEFA14A | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,7.01,8.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| 8-K | 5.07,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEFA14A | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.